Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Aug;72(2):257–267. doi: 10.1038/bjc.1995.323

Tumour vasculature--a potential therapeutic target.

C T Baillie 1, M C Winslet 1, N J Bradley 1
PMCID: PMC2034004  PMID: 7543770

Abstract

The tumour vasculature is vital for the establishment, growth and metastasis of solid tumours. Its physiological properties limit the effectiveness of conventional anti-cancer strategies. Therapeutic approaches directed at the tumour vasculature are reviewed, suggesting the potential of anti-angiogenesis and the targeting of vascular proliferation antigens as cancer treatments.

Full text

PDF
259

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham J. A., Mergia A., Whang J. L., Tumolo A., Friedman J., Hjerrild K. A., Gospodarowicz D., Fiddes J. C. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science. 1986 Aug 1;233(4763):545–548. doi: 10.1126/science.2425435. [DOI] [PubMed] [Google Scholar]
  2. Albo D., Granick M. S., Jhala N., Atkinson B., Solomon M. P. The relationship of angiogenesis to biological activity in human squamous cell carcinomas of the head and neck. Ann Plast Surg. 1994 Jun;32(6):588–594. doi: 10.1097/00000637-199406000-00005. [DOI] [PubMed] [Google Scholar]
  3. Alliegro M. C., Alliegro M. A., Cragoe E. J., Jr, Glaser B. M. Amiloride inhibition of angiogenesis in vitro. J Exp Zool. 1993 Nov 1;267(3):245–252. doi: 10.1002/jez.1402670302. [DOI] [PubMed] [Google Scholar]
  4. Barrie R., Woltering E. A., Hajarizadeh H., Mueller C., Ure T., Fletcher W. S. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res. 1993 Oct;55(4):446–450. doi: 10.1006/jsre.1993.1167. [DOI] [PubMed] [Google Scholar]
  5. Begg A. C., Terry N. H. Modification of stromal radiosensitivity by misonidazole and WR-2721. Br J Radiol. 1983 Aug;56(668):565–570. doi: 10.1259/0007-1285-56-668-565. [DOI] [PubMed] [Google Scholar]
  6. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am J Ophthalmol. 1978 Oct;86(4):455–461. doi: 10.1016/0002-9394(78)90289-1. [DOI] [PubMed] [Google Scholar]
  7. Bicknell R., Harris A. L. Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol. 1992 Dec;3(6):399–407. [PubMed] [Google Scholar]
  8. Bicknell R., Harris A. L. Novel growth regulatory factors and tumour angiogenesis. Eur J Cancer. 1991;27(6):781–785. doi: 10.1016/0277-5379(91)90189-k. [DOI] [PubMed] [Google Scholar]
  9. Blei F., Wilson E. L., Mignatti P., Rifkin D. B. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol. 1993 Jun;155(3):568–578. doi: 10.1002/jcp.1041550315. [DOI] [PubMed] [Google Scholar]
  10. Bloksma N., Hofhuis F., Benaissa-Trouw B., Willers J. Endotoxin-induced release of tumour necrosis factor and interferon in vivo is inhibited by prior adrenoceptor blockade. Cancer Immunol Immunother. 1982;14(1):41–45. doi: 10.1007/BF00199431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bosari S., Lee A. K., DeLellis R. A., Wiley B. D., Heatley G. J., Silverman M. L. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol. 1992 Jul;23(7):755–761. doi: 10.1016/0046-8177(92)90344-3. [DOI] [PubMed] [Google Scholar]
  12. Bruland O. S., Fodstad O., Stenwig A. E., Pihl A. Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. Cancer Res. 1988 Sep 15;48(18):5302–5309. [PubMed] [Google Scholar]
  13. Bugelski P. J., Porter C. W., Dougherty T. J. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res. 1981 Nov;41(11 Pt 1):4606–4612. [PubMed] [Google Scholar]
  14. Burrows F. J., Thorpe P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8996–9000. doi: 10.1073/pnas.90.19.8996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Burrows F. J., Watanabe Y., Thorpe P. E. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Cancer Res. 1992 Nov 1;52(21):5954–5962. [PubMed] [Google Scholar]
  16. Carmichael D. F., Sommer A., Thompson R. C., Anderson D. C., Smith C. G., Welgus H. G., Stricklin G. P. Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2407–2411. doi: 10.1073/pnas.83.8.2407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Castronovo V., Stetler-Stevenson W. G., Sobel M. E., Liotta L. A. Molecular inhibition of cancer cell invasion and metastasis. Princess Takamatsu Symp. 1991;22:319–337. [PubMed] [Google Scholar]
  19. Cheifetz S., Bellón T., Calés C., Vera S., Bernabeu C., Massagué J., Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992 Sep 25;267(27):19027–19030. [PubMed] [Google Scholar]
  20. Chodak G. W., Haudenschild C., Gittes R. F., Folkman J. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg. 1980 Dec;192(6):762–771. doi: 10.1097/00000658-198012000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Clapp C., Martial J. A., Guzman R. C., Rentier-Delure F., Weiner R. I. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology. 1993 Sep;133(3):1292–1299. doi: 10.1210/endo.133.3.7689950. [DOI] [PubMed] [Google Scholar]
  22. Clarke M. S., West D. C. The identification of proliferation and tumour-induced proteins in human endothelial cells: a possible target for tumour therapy. Electrophoresis. 1991 Jul-Aug;12(7-8):500–508. doi: 10.1002/elps.1150120708. [DOI] [PubMed] [Google Scholar]
  23. Clauss M., Murray J. C., Vianna M., de Waal R., Thurston G., Nawroth P., Gerlach H., Bach R., Familletti P. C., Stern D. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem. 1990 Apr 25;265(12):7078–7083. [PubMed] [Google Scholar]
  24. Danesi R., Del Bianchi S., Soldani P., Campagni A., La Rocca R. V., Myers C. E., Paparelli A., Del Tacca M. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer. 1993 Nov;68(5):932–938. doi: 10.1038/bjc.1993.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer. 1982 Jan;45(1):136–139. doi: 10.1038/bjc.1982.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Denekamp J., Hobson B. Endothelial-cell proliferation in experimental tumours. Br J Cancer. 1982 Nov;46(5):711–720. doi: 10.1038/bjc.1982.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol. 1993 Mar;66(783):181–196. doi: 10.1259/0007-1285-66-783-181. [DOI] [PubMed] [Google Scholar]
  28. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990 Nov;9(3):267–282. doi: 10.1007/BF00046365. [DOI] [PubMed] [Google Scholar]
  29. Derynck R., Jarrett J. A., Chen E. Y., Eaton D. H., Bell J. R., Assoian R. K., Roberts A. B., Sporn M. B., Goeddel D. V. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985 Aug 22;316(6030):701–705. doi: 10.1038/316701a0. [DOI] [PubMed] [Google Scholar]
  30. Dvorak H. F., Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst. 1989 Apr 5;81(7):497–502. doi: 10.1093/jnci/81.7.497. [DOI] [PubMed] [Google Scholar]
  31. Dvorak H. F., Nagy J. A., Dvorak A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells. 1991 Mar;3(3):77–85. [PubMed] [Google Scholar]
  32. Dvorak H. F., Nagy J. A., Dvorak J. T., Dvorak A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988 Oct;133(1):95–109. [PMC free article] [PubMed] [Google Scholar]
  33. Endrich B., Zweifach B. W., Reinhold H. S., Intaglietta M. Quantitative studies of microcirculatory function in malignant tissue: influence of temperature on microvascular hemodynamics during the early growth of the BA 1112 rat sarcoma. Int J Radiat Oncol Biol Phys. 1979 Nov-Dec;5(11-12):2021–2030. doi: 10.1016/0360-3016(79)90954-4. [DOI] [PubMed] [Google Scholar]
  34. Esch F., Baird A., Ling N., Ueno N., Hill F., Denoroy L., Klepper R., Gospodarowicz D., Böhlen P., Guillemin R. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A. 1985 Oct;82(19):6507–6511. doi: 10.1073/pnas.82.19.6507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Esch F., Ueno N., Baird A., Hill F., Denoroy L., Ling N., Gospodarowicz D., Guillemin R. Primary structure of bovine brain acidic fibroblast growth factor (FGF). Biochem Biophys Res Commun. 1985 Dec 17;133(2):554–562. doi: 10.1016/0006-291x(85)90942-8. [DOI] [PubMed] [Google Scholar]
  36. Fajardo L. F., Schreiber A. B., Kelly N. I., Hahn G. M. Thermal sensitivity of endothelial cells. Radiat Res. 1985 Aug;103(2):276–285. [PubMed] [Google Scholar]
  37. Fan T. P., Hu D. E., Guard S., Gresham G. A., Watling K. J. Stimulation of angiogenesis by substance P and interleukin-1 in the rat and its inhibition by NK1 or interleukin-1 receptor antagonists. Br J Pharmacol. 1993 Sep;110(1):43–49. doi: 10.1111/j.1476-5381.1993.tb13769.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Fang W., Hartmann N., Chow D. T., Riegel A. T., Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem. 1992 Dec 25;267(36):25889–25897. [PubMed] [Google Scholar]
  39. Fernandez L. A., Twickler J., Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med. 1985 Feb;105(2):141–145. [PubMed] [Google Scholar]
  40. Fett J. W., Strydom D. J., Lobb R. R., Alderman E. M., Bethune J. L., Riordan J. F., Vallee B. L. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985 Sep 24;24(20):5480–5486. doi: 10.1021/bi00341a030. [DOI] [PubMed] [Google Scholar]
  41. Finnis C., Dodsworth N., Pollitt C. E., Carr G., Sleep D. Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. Eur J Biochem. 1993 Feb 15;212(1):201–210. doi: 10.1111/j.1432-1033.1993.tb17651.x. [DOI] [PubMed] [Google Scholar]
  42. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972 Mar;175(3):409–416. doi: 10.1097/00000658-197203000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Folkman J., Ingber D. E. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg. 1987 Sep;206(3):374–383. doi: 10.1097/00000658-198709000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971 Feb 1;133(2):275–288. doi: 10.1084/jem.133.2.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175–203. doi: 10.1016/s0065-230x(08)60946-x. [DOI] [PubMed] [Google Scholar]
  46. Folkman J., Weisz P. B., Joullié M. M., Li W. W., Ewing W. R. Control of angiogenesis with synthetic heparin substitutes. Science. 1989 Mar 17;243(4897):1490–1493. doi: 10.1126/science.2467380. [DOI] [PubMed] [Google Scholar]
  47. Fox S. B., Gatter K. C., Bicknell R., Going J. J., Stanton P., Cooke T. G., Harris A. L. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res. 1993 Sep 15;53(18):4161–4163. [PubMed] [Google Scholar]
  48. Fregene T. A., Khanuja P. S., Noto A. C., Gehani S. K., Van Egmont E. M., Luz D. A., Pienta K. J. Tumor-associated angiogenesis in prostate cancer. Anticancer Res. 1993 Nov-Dec;13(6B):2377–2381. [PubMed] [Google Scholar]
  49. Freudenberg N., Riese K. H., Freudenberg M. A. The vascular endothelial system. Structure--function--pathology--reaction to endotoxin shock--methods of investigation. Veroff Pathol. 1983;120:1–114. [PubMed] [Google Scholar]
  50. Fràter-Schröder M., Risau W., Hallmann R., Gautschi P., Böhlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5277–5281. doi: 10.1073/pnas.84.15.5277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Furukawa T., Yoshimura A., Sumizawa T., Haraguchi M., Akiyama S., Fukui K., Ishizawa M., Yamada Y. Angiogenic factor. Nature. 1992 Apr 23;356(6371):668–668. doi: 10.1038/356668a0. [DOI] [PubMed] [Google Scholar]
  52. Gimbrone M. A., Jr, Cotran R. S., Leapman S. B., Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst. 1974 Feb;52(2):413–427. doi: 10.1093/jnci/52.2.413. [DOI] [PubMed] [Google Scholar]
  53. Gimbrone M. A., Jr, Leapman S. B., Cotran R. S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972 Aug 1;136(2):261–276. doi: 10.1084/jem.136.2.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Good D. J., Polverini P. J., Rastinejad F., Le Beau M. M., Lemons R. S., Frazier W. A., Bouck N. P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624–6628. doi: 10.1073/pnas.87.17.6624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Gougos A., Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem. 1990 May 25;265(15):8361–8364. [PubMed] [Google Scholar]
  56. Grant D. S., Tashiro K., Segui-Real B., Yamada Y., Martin G. R., Kleinman H. K. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell. 1989 Sep 8;58(5):933–943. doi: 10.1016/0092-8674(89)90945-8. [DOI] [PubMed] [Google Scholar]
  57. Gunduz N. Cytokinetics of tumour and endothelial cells and vascularization of lung metastases in C3H/He mice. Cell Tissue Kinet. 1981 Jul;14(4):343–363. doi: 10.1111/j.1365-2184.1981.tb00542.x. [DOI] [PubMed] [Google Scholar]
  58. Hagemeier H. H., Vollmer E., Goerdt S., Schulze-Osthoff K., Sorg C. A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int J Cancer. 1986 Oct 15;38(4):481–488. doi: 10.1002/ijc.2910380405. [DOI] [PubMed] [Google Scholar]
  59. Hart M. N., DeBault L. E., Sadewasser K. L., Cancilla P. A., Henriquez E. M. Morphologic effects of antibody to mouse brain endothelium in vivo. J Neuropathol Exp Neurol. 1981 Jan;40(1):84–91. [PubMed] [Google Scholar]
  60. Hill S., Williams K. B., Denekamp J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1419–1424. doi: 10.1016/0277-5379(89)90099-0. [DOI] [PubMed] [Google Scholar]
  61. Hirst D. G., Denekamp J., Hobson B. Proliferation kinetics of endothelial and tumour cells in three mouse mammary carcinomas. Cell Tissue Kinet. 1982 May;15(3):251–261. doi: 10.1111/j.1365-2184.1982.tb01044.x. [DOI] [PubMed] [Google Scholar]
  62. Horak E. R., Leek R., Klenk N., LeJeune S., Smith K., Stuart N., Greenall M., Stepniewska K., Harris A. L. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992 Nov 7;340(8828):1120–1124. doi: 10.1016/0140-6736(92)93150-l. [DOI] [PubMed] [Google Scholar]
  63. Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991 Nov 15;51(22):6180–6184. [PubMed] [Google Scholar]
  64. Hori K., Suzuki M., Tanda S., Saito S. In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res. 1990 Mar;81(3):279–288. doi: 10.1111/j.1349-7006.1990.tb02562.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Ingber D. E., Folkman J. How does extracellular matrix control capillary morphogenesis? Cell. 1989 Sep 8;58(5):803–805. doi: 10.1016/0092-8674(89)90928-8. [DOI] [PubMed] [Google Scholar]
  66. Ingber D. Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem. 1991 Nov;47(3):236–241. doi: 10.1002/jcb.240470309. [DOI] [PubMed] [Google Scholar]
  67. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990 Dec 6;348(6301):555–557. doi: 10.1038/348555a0. [DOI] [PubMed] [Google Scholar]
  68. Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C., Hagiwara K., Usuki K., Takaku F., Risau W., Heldin C. H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature. 1989 Apr 13;338(6216):557–562. doi: 10.1038/338557a0. [DOI] [PubMed] [Google Scholar]
  69. Kallinowski F., Schaefer C., Tyler G., Vaupel P. In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer. 1989 Oct;60(4):555–560. doi: 10.1038/bjc.1989.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Kao J., Ryan J., Brett G., Chen J., Shen H., Fan Y. G., Godman G., Familletti P. C., Wang F., Pan Y. C. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem. 1992 Oct 5;267(28):20239–20247. [PubMed] [Google Scholar]
  71. Keck P. J., Hauser S. D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989 Dec 8;246(4935):1309–1312. doi: 10.1126/science.2479987. [DOI] [PubMed] [Google Scholar]
  72. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 Apr 29;362(6423):841–844. doi: 10.1038/362841a0. [DOI] [PubMed] [Google Scholar]
  73. Klagsbrun M., D'Amore P. A. Regulators of angiogenesis. Annu Rev Physiol. 1991;53:217–239. doi: 10.1146/annurev.ph.53.030191.001245. [DOI] [PubMed] [Google Scholar]
  74. Knighton D., Ausprunk D., Tapper D., Folkman J. Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer. 1977 Mar;35(3):347–356. doi: 10.1038/bjc.1977.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Kondo S., Asano M., Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun. 1993 Aug 16;194(3):1234–1241. doi: 10.1006/bbrc.1993.1955. [DOI] [PubMed] [Google Scholar]
  76. Kotasek D., Vercellotti G. M., Ochoa A. C., Bach F. H., White J. G., Jacob H. S. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res. 1988 Oct 1;48(19):5528–5532. [PubMed] [Google Scholar]
  77. Kull F. C., Jr, Brent D. A., Parikh I., Cuatrecasas P. Chemical identification of a tumor-derived angiogenic factor. Science. 1987 May 15;236(4803):843–845. doi: 10.1126/science.2437656. [DOI] [PubMed] [Google Scholar]
  78. Kurachi K., Davie E. W., Strydom D. J., Riordan J. F., Vallee B. L. Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry. 1985 Sep 24;24(20):5494–5499. doi: 10.1021/bi00341a032. [DOI] [PubMed] [Google Scholar]
  79. Lastres P., Bellon T., Cabañas C., Sanchez-Madrid F., Acevedo A., Gougos A., Letarte M., Bernabeu C. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol. 1992 Feb;22(2):393–397. doi: 10.1002/eji.1830220216. [DOI] [PubMed] [Google Scholar]
  80. Lazo J. S. Endothelial injury caused by antineoplastic agents. Biochem Pharmacol. 1986 Jun 15;35(12):1919–1923. doi: 10.1016/0006-2952(86)90720-3. [DOI] [PubMed] [Google Scholar]
  81. Leibovich S. J., Polverini P. J., Shepard H. M., Wiseman D. M., Shively V., Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature. 1987 Oct 15;329(6140):630–632. doi: 10.1038/329630a0. [DOI] [PubMed] [Google Scholar]
  82. Leone A., Flatow U., King C. R., Sandeen M. A., Margulies I. M., Liotta L. A., Steeg P. S. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell. 1991 Apr 5;65(1):25–35. doi: 10.1016/0092-8674(91)90404-m. [DOI] [PubMed] [Google Scholar]
  83. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989 Dec 8;246(4935):1306–1309. doi: 10.1126/science.2479986. [DOI] [PubMed] [Google Scholar]
  84. Lien W. M., Ackerman N. B. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery. 1970 Aug;68(2):334–340. [PubMed] [Google Scholar]
  85. Macchiarini P., Fontanini G., Hardin M. J., Squartini F., Angeletti C. A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 1992 Jul 18;340(8812):145–146. doi: 10.1016/0140-6736(92)93217-b. [DOI] [PubMed] [Google Scholar]
  86. Maione T. E., Gray G. S., Petro J., Hunt A. J., Donner A. L., Bauer S. I., Carson H. F., Sharpe R. J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science. 1990 Jan 5;247(4938):77–79. doi: 10.1126/science.1688470. [DOI] [PubMed] [Google Scholar]
  87. Marquardt H., Hunkapiller M. W., Hood L. E., Todaro G. J. Rat transforming growth factor type 1: structure and relation to epidermal growth factor. Science. 1984 Mar 9;223(4640):1079–1082. doi: 10.1126/science.6320373. [DOI] [PubMed] [Google Scholar]
  88. Matsubara T., Saura R., Hirohata K., Ziff M. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest. 1989 Jan;83(1):158–167. doi: 10.1172/JCI113853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Matsuzaki K., Yoshitake Y., Matuo Y., Sasaki H., Nishikawa K. Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc Natl Acad Sci U S A. 1989 Dec;86(24):9911–9915. doi: 10.1073/pnas.86.24.9911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. McAuslan B. R., Hoffman H. Endothelium stimulating factor from Walker carcinoma cells. Relation to tumor angiogenic factor. Exp Cell Res. 1979 Mar 1;119(1):181–190. doi: 10.1016/0014-4827(79)90347-1. [DOI] [PubMed] [Google Scholar]
  91. Millauer B., Shawver L. K., Plate K. H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994 Feb 10;367(6463):576–579. doi: 10.1038/367576a0. [DOI] [PubMed] [Google Scholar]
  92. Moghaddam A., Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry. 1992 Dec 8;31(48):12141–12146. doi: 10.1021/bi00163a024. [DOI] [PubMed] [Google Scholar]
  93. Morris P. B., Ellis M. N., Swain J. L. Angiogenic potency of nucleotide metabolites: potential role in ischemia-induced vascular growth. J Mol Cell Cardiol. 1989 Apr;21(4):351–358. doi: 10.1016/0022-2828(89)90645-7. [DOI] [PubMed] [Google Scholar]
  94. Moses M. A., Sudhalter J., Langer R. Identification of an inhibitor of neovascularization from cartilage. Science. 1990 Jun 15;248(4961):1408–1410. doi: 10.1126/science.1694043. [DOI] [PubMed] [Google Scholar]
  95. Motro B., Itin A., Sachs L., Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3092–3096. doi: 10.1073/pnas.87.8.3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Muller W. A., Ratti C. M., McDonnell S. L., Cohn Z. A. A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med. 1989 Aug 1;170(2):399–414. doi: 10.1084/jem.170.2.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Murata J., Saiki I., Makabe T., Tsuta Y., Tokura S., Azuma I. Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res. 1991 Jan 1;51(1):22–26. [PubMed] [Google Scholar]
  98. Murray J. C., Randhawa V., Denekamp J. The effects of melphalan and misonidazole on the vasculature of a murine sarcoma. Br J Cancer. 1987 Mar;55(3):233–238. doi: 10.1038/bjc.1987.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Murray J. C., Smith K. A., Lauk S. Vascular markers for murine tumours. Radiother Oncol. 1989 Nov;16(3):221–234. doi: 10.1016/0167-8140(89)90022-4. [DOI] [PubMed] [Google Scholar]
  100. Odedra R., Weiss J. B. Low molecular weight angiogenesis factors. Pharmacol Ther. 1991;49(1-2):111–124. doi: 10.1016/0163-7258(91)90025-h. [DOI] [PubMed] [Google Scholar]
  101. Ohtsu A., Fujii K., Kurozumi S. Induction of angiogenic response by chemically stable prostacyclin analogs. Prostaglandins Leukot Essent Fatty Acids. 1988 Jul;33(1):35–39. doi: 10.1016/0952-3278(88)90120-2. [DOI] [PubMed] [Google Scholar]
  102. Oikawa T., Hirotani K., Ogasawara H., Katayama T., Nakamura O., Iwaguchi T., Hiragun A. Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol. 1990 Mar 20;178(2):247–250. doi: 10.1016/0014-2999(90)90483-m. [DOI] [PubMed] [Google Scholar]
  103. Oikawa T., Hirotani K., Shimamura M., Ashino-Fuse H., Iwaguchi T. Powerful antiangiogenic activity of herbimycin A (named angiostatic antibiotic). J Antibiot (Tokyo) 1989 Jul;42(7):1202–1204. doi: 10.7164/antibiotics.42.1202. [DOI] [PubMed] [Google Scholar]
  104. Oikawa T., Shimamura M., Ashino-Fuse H., Iwaguchi T., Ishizuka M., Takeuchi T. Inhibition of angiogenesis by 15-deoxyspergualin. J Antibiot (Tokyo) 1991 Sep;44(9):1033–1035. doi: 10.7164/antibiotics.44.1033. [DOI] [PubMed] [Google Scholar]
  105. Oosterwijk E., Ruiter D. J., Wakka J. C., Huiskens-van der Meij J. W., Jonas U., Fleuren G. J., Zwartendijk J., Hoedemaeker P., Warnaar S. O. Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma. Am J Pathol. 1986 May;123(2):301–309. [PMC free article] [PubMed] [Google Scholar]
  106. Orchard P. J., Smith C. M., 3rd, Woods W. G., Day D. L., Dehner L. P., Shapiro R. Treatment of haemangioendotheliomas with alpha interferon. Lancet. 1989 Sep 2;2(8662):565–567. doi: 10.1016/s0140-6736(89)90694-6. [DOI] [PubMed] [Google Scholar]
  107. Phillips P., Kumar S. Tumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum. Int J Cancer. 1979 Jan 15;23(1):82–88. doi: 10.1002/ijc.2910230115. [DOI] [PubMed] [Google Scholar]
  108. Plate K. H., Breier G., Weich H. A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992 Oct 29;359(6398):845–848. doi: 10.1038/359845a0. [DOI] [PubMed] [Google Scholar]
  109. Rastinejad F., Polverini P. J., Bouck N. P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell. 1989 Feb 10;56(3):345–355. doi: 10.1016/0092-8674(89)90238-9. [DOI] [PubMed] [Google Scholar]
  110. Reilly T. M., Taylor D. S., Herblin W. F., Thoolen M. J., Chiu A. T., Watson D. W., Timmermans P. B. Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo. Biochem Biophys Res Commun. 1989 Oct 31;164(2):736–743. doi: 10.1016/0006-291x(89)91521-0. [DOI] [PubMed] [Google Scholar]
  111. Rettig W. J., Garin-Chesa P., Healey J. H., Su S. L., Jaffe E. A., Old L. J. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10832–10836. doi: 10.1073/pnas.89.22.10832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Risau W., Drexler H., Mironov V., Smits A., Siegbahn A., Funa K., Heldin C. H. Platelet-derived growth factor is angiogenic in vivo. Growth Factors. 1992;7(4):261–266. doi: 10.3109/08977199209046408. [DOI] [PubMed] [Google Scholar]
  113. Roberts A. B., Sporn M. B., Assoian R. K., Smith J. M., Roche N. S., Wakefield L. M., Heine U. I., Liotta L. A., Falanga V., Kehrl J. H. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167–4171. doi: 10.1073/pnas.83.12.4167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Rosengard A. M., Krutzsch H. C., Shearn A., Biggs J. R., Barker E., Margulies I. M., King C. R., Liotta L. A., Steeg P. S. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature. 1989 Nov 9;342(6246):177–180. doi: 10.1038/342177a0. [DOI] [PubMed] [Google Scholar]
  115. Schreiber A. B., Winkler M. E., Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science. 1986 Jun 6;232(4755):1250–1253. doi: 10.1126/science.2422759. [DOI] [PubMed] [Google Scholar]
  116. Schultz-Hector S., Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res. 1993 Mar 15;53(6):1444–1449. [PubMed] [Google Scholar]
  117. Senger D. R., Connolly D. T., Van de Water L., Feder J., Dvorak H. F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990 Mar 15;50(6):1774–1778. [PubMed] [Google Scholar]
  118. Shapiro R., Vallee B. L. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2238–2241. doi: 10.1073/pnas.84.8.2238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992 Oct 29;359(6398):843–845. doi: 10.1038/359843a0. [DOI] [PubMed] [Google Scholar]
  120. Sidky Y. A., Borden E. C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987 Oct 1;47(19):5155–5161. [PubMed] [Google Scholar]
  121. Solesvik O. V., Rofstad E. K., Brustad T. Vascular changes in a human malignant melanoma xenograft following single-dose irradiation. Radiat Res. 1984 Apr;98(1):115–128. [PubMed] [Google Scholar]
  122. Srivastava A., Laidler P., Davies R. P., Horgan K., Hughes L. E. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol. 1988 Nov;133(2):419–423. [PMC free article] [PubMed] [Google Scholar]
  123. Star W. M., Marijnissen H. P., van den Berg-Blok A. E., Versteeg J. A., Franken K. A., Reinhold H. S. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 1986 May;46(5):2532–2540. [PubMed] [Google Scholar]
  124. Stetler-Stevenson W. G., Krutzsch H. C., Liotta L. A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem. 1989 Oct 15;264(29):17374–17378. [PubMed] [Google Scholar]
  125. THOMLINSON R. H., GRAY L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955 Dec;9(4):539–549. doi: 10.1038/bjc.1955.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Tamargo R. J., Bok R. A., Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 1991 Jan 15;51(2):672–675. [PubMed] [Google Scholar]
  127. Tannock I. F. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 1970 Oct;30(10):2470–2476. [PubMed] [Google Scholar]
  128. Taylor S., Folkman J. Protamine is an inhibitor of angiogenesis. Nature. 1982 May 27;297(5864):307–312. doi: 10.1038/297307a0. [DOI] [PubMed] [Google Scholar]
  129. Usuki K., Saras J., Waltenberger J., Miyazono K., Pierce G., Thomason A., Heldin C. H. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem Biophys Res Commun. 1992 May 15;184(3):1311–1316. doi: 10.1016/s0006-291x(05)80025-7. [DOI] [PubMed] [Google Scholar]
  130. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989 Dec 1;49(23):6449–6465. [PubMed] [Google Scholar]
  131. Vukanovic J., Passaniti A., Hirata T., Traystman R. J., Hartley-Asp B., Isaacs J. T. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 1993 Apr 15;53(8):1833–1837. [PubMed] [Google Scholar]
  132. Wakamatsu K., Masaki T., Itoh F., Kondo K., Sudo K. Isolation of fatty acid amide as an angiogenic principle from bovine mesentery. Biochem Biophys Res Commun. 1990 Apr 30;168(2):423–429. doi: 10.1016/0006-291x(90)92338-z. [DOI] [PubMed] [Google Scholar]
  133. Wang J. M., Kumar S., Pye D., van Agthoven A. J., Krupinski J., Hunter R. D. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer. 1993 May 28;54(3):363–370. doi: 10.1002/ijc.2910540303. [DOI] [PubMed] [Google Scholar]
  134. Ward W. F., Solliday N. H., Molteni A., Port C. D. Radiation injury in rat lung. II. Angiotensin-converting enzyme activity. Radiat Res. 1983 Nov;96(2):294–300. [PubMed] [Google Scholar]
  135. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E. N., Moore D. H., Meli S., Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992 Dec 16;84(24):1875–1887. doi: 10.1093/jnci/84.24.1875. [DOI] [PubMed] [Google Scholar]
  136. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol. 1993 Nov;10(4):302–313. [PubMed] [Google Scholar]
  137. Weiss J. B., Brown R. A., Kumar S., Phillips P. An angiogenic factor isolated from tumours: a potent low-molecular-weight compound. Br J Cancer. 1979 Sep;40(3):493–496. doi: 10.1038/bjc.1979.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Weiss R. B., Greene R. F., Knight R. D., Collins J. M., Pelosi J. J., Sulkes A., Curt G. A. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Res. 1988 Oct 15;48(20):5878–5882. [PubMed] [Google Scholar]
  139. West C. M., West D. C., Kumar S., Moore J. V. A comparison of the sensitivity to photodynamic treatment of endothelial and tumour cells in different proliferative states. Int J Radiat Biol. 1990 Jul;58(1):145–156. doi: 10.1080/09553009014551501. [DOI] [PubMed] [Google Scholar]
  140. Yates R. A., Nanney L. B., Gates R. E., King L. E., Jr Epidermal growth factor and related growth factors. Int J Dermatol. 1991 Oct;30(10):687–694. doi: 10.1111/j.1365-4362.1991.tb02609.x. [DOI] [PubMed] [Google Scholar]
  141. Ziche M., Gullino P. M. Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst. 1982 Aug;69(2):483–487. [PubMed] [Google Scholar]
  142. Ziche M., Morbidelli L., Pacini M., Geppetti P., Alessandri G., Maggi C. A. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990 Sep;40(2):264–278. doi: 10.1016/0026-2862(90)90024-l. [DOI] [PubMed] [Google Scholar]
  143. Zwi L. J., Baguley B. C., Gavin J. B., Wilson W. R. The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. Br J Cancer. 1990 Aug;62(2):231–237. doi: 10.1038/bjc.1990.266. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES